Publication
Abstract
Realization of a part of clinical trial called Double-blind, randmizovaná, parallel group, multicenter study evaluating the efficacy and safety of mirabegron compared with solifenacin in patients with overactive bladder (OAB) treated with antimuscarinic agents and unsatisfied due to lack of efficacy